From vaccines to therapeutics, the emergence of mRNA as a versatile and potent biological tool across the healthcare landscape continues to demand new, innovative ways to scale mRNA manufacturing. To ...
Quantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink’s ...
RNA viruses frequently bypass the conventional 5′ cap‐dependent mechanism of translation by employing alternative strategies that enable them to commandeer the host’s translational machinery. A ...
As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.
The donation commemorates the launch of TriLink’s first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price.
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces ...
This article is based on a poster originally authored by Harrison H, Glen A , Andrews B, Bayle E, Duncan C, Fyfe M , Guest P, Rausch O , Swain C, Thomas B, Zemla-Brown A, Baric R, Chen Y, Froggatt H, ...
Mateusz Wilamowski, Darren A. Sherrell, George Minasov, Youngchang Kim, Ludmilla Shuvalova, Alex Lavens, Ryan Chard, Natalia Maltseva, Robert Jedrzejczak, Monica ...
Viruses use the molecular repertoire of the host cell to replicate. Researchers from the Cluster of Excellence ImmunoSensation2 at the University of Bonn, together with Japanese researchers, want to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback